Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000932471-25-000787·Aclaris Therapeutics, Inc.
Schedule 13G ownership disclosure
Aclaris Therapeutics Inc
Common Stock · CUSIP: 00461U105
Event date: 2025-06-30
- Filing-level shares
- 6,662,063
- Percent of class
- 6.15%
- The Vanguard Group
Shares: 6,662,063 · Class: 6.15%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000932471-25-000787
- Form type
- SCHEDULE 13G
- Filer
- Aclaris Therapeutics, Inc.
- CIK
- CIK 1557746
- Filed
- Jul 29, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership